Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 3301 AL 3315

Improvements of symptoms of Alzheimer`s disease by inhibition of the angiotensin system

Quitterer U, AbdAlla S.

Pharmacol Res. 2020 Apr;154:104230. doi: 10.1016/j.phrs.2019.04.014. Epub 2019 Apr 13.

Effect of genetic polymorphisms on Alzheimer's disease treatment outcomes: an update

Sumirtanurdin R, Thalib AY, Cantona K, Abdulah R.

Clin Interv Aging. 2019 Mar 29;14:631-642. doi: 10.2147/CIA.S200109. eCollection 2019.

Variability in the validity and reliability of outcome measures identified in a systematic review to assess treatment efficacy of cognitive enhancers for Alzheimer's Dementia

Soobiah C, Tadrous M, Knowles S, Blondal E, Ashoor HM, Ghassemi M, Khan PA, Ho J, Tricco AC, Straus SE.

PLoS One. 2019 Apr 18;14(4):e0215225. doi: 10.1371/journal.pone.0215225. eCollection 2019.

Non-conventional compounds with potential therapeutic effects against Alzheimer's disease

de Castro AA, Soares FV, Pereira AF, Polisel DA, Caetano MS, Leal DHS, da Cunha EFF, Nepovimova E, Kuca K, Ramalho TC.

Expert Rev Neurother. 2019 May;19(5):375-395. doi: 10.1080/14737175.2019.1608823. Epub 2019 Apr 29.

Effects of an Interdisciplinary Care Team on the Management of Alzheimer's Disease in China

Chen C, Huang Y, Liu C, Xu Y, Zheng L, Li J.

J Gerontol Nurs. 2019 May 1;45(5):39-45. doi: 10.3928/00989134-20190318-01.

Transcranial Direct Current Stimulation Improves Cognitive Function in Mild to Moderate Alzheimer Disease: A Meta-Analysis

Cai M, Guo Z, Xing G, Peng H, Zhou L, Chen H, McClure MA, He L, Xiong L, He B, Du F, Mu Q.

Alzheimer Dis Assoc Disord. 2019 Apr-Jun;33(2):170-178. doi: 10.1097/WAD.0000000000000304.

The Y(682)ENPTY(687) motif of APP: Progress and insights toward a targeted therapy for Alzheimer's disease patients

Matrone C, Iannuzzi F, Annunziato L.

Ageing Res Rev. 2019 Jul;52:120-128. doi: 10.1016/j.arr.2019.04.003. Epub 2019 Apr 27.

Safety and tolerability of donepezil 23 mg with or without intermediate dose titration in patients with Alzheimer's disease taking donepezil 10 mg: a multicenter, randomized, open-label, parallel-design, three-arm, prospective trial

Hong YJ, Han HJ, Youn YC, Park KW, Yang DW, Kim S, Kim HJ, Kim JE, Lee JH; ODESA study (Optimal Dose Escalation Strategy to Successful Achievement of High Dose Donepezil 23 mg).

Alzheimers Res Ther. 2019 May 1;11(1):37. doi: 10.1186/s13195-019-0492-1.

Novel Therapeutic Potentials of Taxifolin for Amyloid-β-associated Neurodegenerative Diseases and Other Diseases: Recent Advances and Future Perspectives

Tanaka M, Saito S, Inoue T, Satoh-Asahara N, Ihara M.

Int J Mol Sci. 2019 Apr 30;20(9):2139. doi: 10.3390/ijms20092139.

Peripheral vascular responses to acetylcholine as a predictive tool for response to cholinesterase inhibitors in Alzheimer's disease

Connelly PJ, Adams F, Tayar ZI, Khan F.

BMC Neurol. 2019 May 3;19(1):88. doi: 10.1186/s12883-019-1316-4.

Therapeutic Strategies for Alzheimer's Disease in the View of Diabetes Mellitus

Ohyagi Y, Miyoshi K, Nakamura N.

Adv Exp Med Biol. 2019;1128:227-248. doi: 10.1007/978-981-13-3540-2_11.

Editorial: Failure After Failure. What Next in AD Drug Development?

Aisen PS.

J Prev Alzheimers Dis. 2019;6(3):150. doi: 10.14283/jpad.2019.23.

Silymarin's Inhibition and Treatment Effects for Alzheimer's Disease

Guo H, Cao H, Cui X, Zheng W, Wang S, Yu J, Chen Z.

Molecules. 2019 May 6;24(9):1748. doi: 10.3390/molecules24091748.

Effect of CYP2D6 and CYP3A4 Genotypes on the Efficacy of Cholinesterase Inhibitors in Southern Chinese Patients With Alzheimer's Disease

Ma SL, Tang NLS, Wat KHY, Tang JHY, Lau KH, Law CB, Chiu J, Tam CCW, Poon TK, Lin KL, Kng CPL, Kong HL, Chan TY, Chan WC, Lam LCW.

Am J Alzheimers Dis Other Demen. 2019 Aug;34(5):302-307. doi: 10.1177/1533317519848237. Epub 2019 May 7.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias